NEW SCIENCE, DISEASES AND DRUGS DEMAND NEW APPROACHES
Whitepaper written by: Tom Ruane, Senior Director, Patient Recruitment PAREXEL
Provided by: PAREXEL
Medicines for rare diseases accounted for 41% of new FDA-approved drugs in 2016. However, developing new treatments for orphan indications is hugely challenging.
Two of the greatest difficulties consist of finding and recruiting enough subjects to support statistically valid clinical trials and properly and ethically caring for trial patients suffering the quality-of-life (QoL) issues these diseases engender. In this whitepaper, Challenging Conventional Patient Recruitment and Care Strategies for Rare Disease Studies, Tom Ruane, Senior Director, Patient Recruitment PAREXEL discusses how to challenge conventional patient recruitment methods and care strategies to successfully recruit patients for these important studies.
Download this whitepaper for insight on:
- How conventions can get in the way
- Patient-first trial design
- Leveraging technology for the benefit of patients and clinicians
PAREXEL is a sponsor of the upcoming World Orphan Drug Congress USA 2017 being held April 19-21,2017 at the Washington Marriott Wardman Park in Washington D.C. Make sure to visit PAREXEL at booth #118 and see Sy Pretorius, Senior Vice President and Chief Scientific Officer moderate the Keynote CEO panel: Driving the Future of the Orphan Drug Market – Adapting to Change, Fostering Innovation and Transforming Patients’ lives at on April 20th at 9:20am. Huron, Jennifer. “Orphan Drugs Represent 41% of All New Medications.” National Organization for Rare Disorders.